非小细胞肺癌合并慢性肺病患者的检查点抑制剂肺炎:ILD、COPD与一般人群的全球联邦数据库比较研究
本研究利用TriNetX全球联邦数据库开展回顾性队列研究,纳入2017年1月至2023年1月接受免疫检查点抑制剂(ICI)治疗的患者,比较间质性肺疾病(ILD)、慢阻肺(COPD)及无已知肺病人群的检查点抑制剂肺炎(CIP)发生率、发病时间、复发及结局。经1:1:1倾向性评分匹配后,ILD组CIP发生率最高(4.6%),高于COPD组(1.9%)和对照组(1.5%)(p < 0.001);ILD合并CIP患者的复发率、全因住院率和全因死亡率均更高。
要点
- ILD患者ICI治疗后CIP发生率4.6%,显著高于COPD的1.9%和对照的1.5%。
- ILD合并CIP患者复发率16.4%、全因住院率61%、全因死亡率41.1%,均高于COPD和对照。
- 三组CIP发病时间相似,但ILD患者一旦发生CIP结局更差,需加强监测。
核心结论
- ILD显著增加CIP发生风险并恶化相关结局,包括复发和死亡。
- 研究结果支持对接受ICI治疗的ILD患者进行更密切的监测和风险分层。
研究设计与样本
- 回顾性队列研究,使用TriNetX研究网络识别2017年1月至2023年1月接受ICI治疗的患者。
- 患者分为ILD组、COPD组和无已知肺病对照组,采用1:1:1倾向性评分匹配调整基线特征。
- 匹配后每组3147例;CIP通过ICD编码识别。
主要发现
- 在184,000余例ICI接受者中,3147例有ILD,8657例有COPD,47,031例无已知肺病。
- 匹配后CIP发生率:ILD组4.6%,COPD组1.9%,对照组1.5%(p < 0.001)。
- 三组CIP发病时间相似。
- ILD合并CIP患者复发率16.4%,高于COPD组的9.1%和对照组的8.3%。
- ILD合并CIP患者全因住院率61%,高于COPD组的40%和对照组的39%;全因死亡率41.1%。
临床怎么用
- 对接受ICI治疗的ILD患者应提高CIP警惕,加强监测和风险分层。
- ILD患者发生CIP后需关注复发、住院和死亡风险,及时干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Checkpoint inhibitor pneumonitis (CIP) is a serious immune-related adverse event. Patients with interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD) may be at increased risk, but data comparing these populations is limited. We aimed to evaluate differences in CIP incidence, onset, recurrence, and outcomes among patients with ILD, COPD, and those without pre-existing lung disease. METHODS: We conducted a retrospective cohort study using the TriNetX Research Network, identifying patients who received immune checkpoint inhibitors (ICIs) between January 2017 and January 2023. Patients were stratified into ILD, COPD, and control groups. CIP was identified using ICD codes. Propensity score matching (1:1:1) was used to adjust for baseline characteristics. Outcomes included CIP incidence, time to onset, recurrence, hospitalisation, and mortality. RESULTS: Among 184,000+ ICI recipients, 3147 had ILD, 8657 had COPD, and 47,031 had no known lung disease. After matching (n = 3147/group), CIP incidence was highest in ILD patients (4.6%) compared to COPD (1.9%) and controls (1.5%) (p < 0.001). Time to CIP onset was similar across groups. ILD patients with CIP had higher recurrence (16.4% vs. 9.1% and 8.3%) and higher all-cause hospitalisation (61% vs. 40% and 39%) compared to COPD and control groups. All-cause mortality was also higher in the ILD-CIP group (41.1%). CONCLUSION: ILD significantly increases the risk of developing CIP and worsens associated outcomes, including recurrence and mortality. These findings support closer surveillance and risk stratification in ICI-treated patients with underlying ILD.
引用
- Maule G, Abuassi M, Sircar S, et al. Checkpoint Inhibitor Pneumonitis in Non-Small Cell Lung Cancer With Chronic Lung Disease: A Comparative Study of ILD, COPD, and the General Population Using a Global Federated Database. Respirology. 2025. PMID: 41371776. doi:10.1002/resp.70180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。